Studies in animal models of AD have shown that treatment with DPP-4 inhibitors (such as saxagliptin, vildagliptin, linagliptin, and sitagliptin) increases GLP-1 expression in the hippocampus and other various brain regions (88–91). Here, DPP4 is linked to Alzheimer disease.